PMID- 17287077
OWN - NLM
STAT- MEDLINE
DCOM- 20070604
LR  - 20151119
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 249
IP  - 1
DP  - 2007 Apr 28
TI  - Application and interpretation of FISH in biomarker studies.
PG  - 97-109
AB  - Emerging genomic and proteomic data is creating new opportunities to identify 
      novel biomarkers that will have pathway-specific therapeutic impact on cancer 
      progression. Molecular cytogenetic and fluorescence in situ hybridization (FISH) 
      methods have been primarily used in discovery genetic research laboratories until 
      recently. New automated analytical platforms based on FISH technologies and 
      tissue microarray methods are providing a rapid means to determine the impact of 
      consistent genomic aberrations in clinical trials, and in studies designed to 
      investigate differential chemotherapeutic response.
FAU - Bayani, Jane
AU  - Bayani J
AD  - Division of Applied Molecular Oncology, Princess Margaret Hospital, University 
      Health Network, 610 University Avenue, Room 9-717, Toronto, Ont., Canada M5G 2M9.
FAU - Squire, Jeremy A
AU  - Squire JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070206
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - *Chromosome Aberrations
MH  - Gene Amplification
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Neoplasms/*genetics
RF  - 104
EDAT- 2007/02/09 09:00
MHDA- 2007/06/05 09:00
CRDT- 2007/02/09 09:00
PHST- 2006/12/13 00:00 [received]
PHST- 2006/12/14 00:00 [accepted]
PHST- 2007/02/09 09:00 [pubmed]
PHST- 2007/06/05 09:00 [medline]
PHST- 2007/02/09 09:00 [entrez]
AID - S0304-3835(06)00698-7 [pii]
AID - 10.1016/j.canlet.2006.12.030 [doi]
PST - ppublish
SO  - Cancer Lett. 2007 Apr 28;249(1):97-109. doi: 10.1016/j.canlet.2006.12.030. Epub 
      2007 Feb 6.